Phase II study of TS-1+Irinotecan+Bevacizumab as second-line treatment in patients with metastatic colorectal cancer refractory to fluoronated pyrimidine, oxaliplatin, and cetuximab therapy

ABSTRACT: Interventions: TS-1+Irinotecan+Bevacizumab therapy Bevacizumab 7.5mg/m2/tri-weekly Irinotecan 150mg/m2/tri-weekly TS-1 80-120mg/day, for 14 days followed by 1 week rest Primary outcome(s): 6-Month Progression Free Survival Rate Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2625708 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR